Clinical trials: Solid Tumor, completed
Cancer
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
This is an open-label, randomized, single-dose, 2-treatment, 2-period, 2-way crossover study with incomplete wash-out in subjects with solid tumors to determine the relative bioavailability of test formulation with lower dimethyl…
- Trial name
- NCT01725100
- Testing
- GSK1120212B (Standard DMSO content), GSK1120212B (Lower DMSO content)
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
RATIONALE: Chemoprotective drugs such as carboxypeptidase-G2 may protect normal cells from the toxic effects of chemotherapy. PURPOSE: Clinical trial to study the effectiveness of carboxypeptidase-G2 in treating nervous system…
- Conditions
- Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00018967
- Testing
- glucarpidase
- Where
- 103 sites in United States, Australia and 2 more
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with docetaxel.
- Trial name
- NCT01957007
- Testing
- Docetaxel, vantictumab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Refractory Solid Tumors
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.
- Trial name
- NCT00394446
- Testing
- MPC-6827
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Myrexis Inc.
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain.
- Trial name
- NCT05506982
- Testing
- Psilocybin, Psychotherapy, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Advanced Solid Tumor
Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib.
- Trial name
- NCT00449280
- Testing
- Sorafenib, Rapamycin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Chicago
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Solid Tumor
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours
CHR-3996 is one of a new class of anti-cancer agents - histone deacetylase inhibitors (HDACi) - that has exhibited pleiotropic activity both in vitro and in vivo against a range of human cancer cells.
- Trial name
- NCT00697879
- Testing
- CHR-3996
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Chroma Therapeutics
Metastatic Solid Tumors (Any Localization)
Exploratory Clinical Study of ¹⁷⁷Lu-CTR-FAPI in Patients With Metastatic Solid Tumors
This is a single-center, non-randomized, single-arm, open-label exploratory clinical study of ¹⁷⁷Lu-CTR-FAPI in patients with FAP-high expressing metastatic solid tumors, with a focus on breast cancer, sarcoma, and thyroid…
- Trial name
- NCT07587996
- Testing
- radionuclide therapy with ¹⁷⁷Lu-CTR-FAPI
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Lanzhou University Second Hospital
Malignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
Phase I trial to determine the dose of imatinib mesylate that is most effective with the least amount of toxic side effects in treating patients who have advanced cancer and kidney failure.
- Trial name
- NCT00026169
- Testing
- imatinib mesylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, B Cell Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma.
- Trial name
- NCT04418141
- Testing
- CN1
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
Pediatric Solid Tumors
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
The purpose of this study is to test the safety and effectiveness of 2 drugs, perifosine in combination with temsirolimus in children with solid tumors.
- Trial name
- NCT01049841
- Testing
- perifosine + temsirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Tumors
Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors
This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.
- Trial name
- NCT00093873
- Testing
- Anti-angiogenesis, AMG 706
- Volunteers
- 71 people
- Sponsor
- Amgen
Advanced Solid Tumors
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and primary efficacy of IBI321 in participants with locally advanced, recurrent, or metastatic…
- Trial name
- NCT04911894
- Testing
- IBI321
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Malignancy, Advanced Solid Tumors
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT01723020
- Testing
- AMG 232
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 107 people
- Sponsor
- Kartos Therapeutics, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the…
- Trial name
- NCT00004059
- Testing
- 7-hydroxystaurosporine, fluorouracil
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Squamous Cell Tumors
A Study of ABT-414 in Subjects With Solid Tumors
A study of ABT-414 in subjects with solid tumors.
- Trial name
- NCT01741727
- Testing
- ABT-414
- Where
- 6 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HRD Cancer, SCLC
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Background: Small cell lung cancer and PARP inhibitor resistant tumors are aggressive cancers. Current treatments for people with these tumors yield little benefit. Researchers want to see if a combination of drugs can help.
- Conditions
- HRD Cancer, SCLC, Advanced Solid Tumors
- Trial name
- NCT04826341
- Testing
- Berzosertib, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Solid Tumors
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to test the efficacy and safety of an experimental drug, demcizumab, when given in combination with pembrolizumab.
- Trial name
- NCT02722954
- Testing
- Demcizumab, Pembrolizumab
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 29 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination…
- Trial name
- NCT00002505
- Testing
- filgrastim, recombinant interferon gamma, tumor cell lysate vaccine therapy
- Where
- 4 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.